MHRA is examining whether those affected have a genetic trait that is leaving them at a greater risk of side effects from the ...

Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP-1 drugs, it targets a hormone that slows stomach emptying. Over 12 weeks, ...

NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

Three months since Suzanne Harrington was prescribed the weight-loss jab Mounjaro, she opens up her diary and reveals all ...

Universal access to GLP-1 receptor agonists for eligible populations could reduce global obesity prevalence by half and save ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Novo Nordisk A/S (NYSE:NVO) stock dropped 2.1% premarket following news that Spain’s health ministry has requested clarification about the company’s obesity awareness campaign, which may have violated ...

Diabetes drug Ozempic and weight-loss jab Wegovy may also reduce the risk of dementia, according to a new study. American ...

Interpol cited a concerning rise in demand for unauthorised weight loss drugs and peptide supplements in Europe and other ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...